Clinical Trials Market Will Exceed $30BN by 2015

August 2011
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p1
Trade Publication
The article discusses projections regarding the future of the pharmaceutical industry as of August 2011. According to the Pharma Clinical Trial Services, revenues for contract research organizations (CRO) was 21.69 billion dollars in 2010, and that by 2015, those figures should exceed 30 billion dollars. To achieve such targets, operating costs will have to be kept low, and as such, more outsourcing to countries like China and India will continue. An overview of Visiongain, an independent media company based in London, England, is offered.


Related Articles

  • Outsourcing Winners in 2014. Langer, Eric // Pharmaceutical Technology;Nov2010, Vol. 34 Issue 11, p112 

    The article focuses on the outsourcing in the biopharmaceutical industry in China and India which is considered as a strategic safety valve by some companies. It states that start-up contract manufacturing organizations in China are not growing as aggressively as predicted prior to the...

  • R&D Outsourcing That Works. Malek, Jan // Pharmaceutical Executive;Mar2000, Vol. 20 Issue 3, p70 

    Provides a framework that will enable pharmaceutical companies and contract research organizations to create stronger outsourcing relationship. Themes of dissatisfaction among companies; Importance of understanding the evolution of research and development outsourcing; Characteristics of...

  • Three Challenges. Nicholas, Judith A.; Squires, Douglas J.; Lennox, R. Ian // Pharmaceutical Executive;Jun2002 Supplement, Vol. 23, p96 

    Presents the challenges facing contract research organizations (CRO). Increase in outsourcing since 1997; Information on how CRO can help increase productivity; Strategies needed by CRO to help customers adapt and profit from changes.

  • By the Numbers.  // Contract Pharma;May2013, Vol. 15 Issue 4, p51 

    Statistics related to the results of a 2013 outsourcing survey in the pharmaceutical industry are presented, including one on the percentage of respondents who employ secondary suppliers for their commercial supply, one on the percentage of respondents whose active pharmaceutical ingredients...

  • How much did your outsourcing spending change in the past year? (by outsourcing decision).  // Contract Pharma;May2013, Vol. 15 Issue 4, p21 

    Several pie graphs are presented which provide data on the percentage of the extent of change in outsourcing spending in 2012 by outsourcing decision including chemistry, analytical and testing services, and research & development (R&D) services.

  • How much do you expect your outsourcing spending to change in the next year? (by outsourcing decision).  // Contract Pharma;May2013, Vol. 15 Issue 4, p49 

    Several pie graphs are presented which provide data on the percentage of the extent of change in pharmaceutical industry's outsourcing spending that respondents expect in 2014 by outsourcing decision including research & development (R&D) services, chemistry, and formulation development.

  • Research & Markets: Lead Generation Strategies & Technologies in Drug Development - Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs.  // Biomedical Market Newsletter;7/5/2011, p625 

    The article focuses on the "Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs" report offered by Research & Markets Ltd. It states that the report provides information on the strategies in...

  • Animal Tester. Pocha, Jehangir S. // Forbes Asia;10/30/2006, Vol. 2 Issue 18, p24 

    The article focuses on the ability of Bridge Pharmaceuticals Corp. to help U.S. pharmaceutical companies outsource laboratory work to China in 2006. Bridge Pharmaceuticals, which is headed by CEO Glenn Rice, is a contract research organization in San Francisco Bay Area, California. According to...

  • Pharma Outsourcing to Grow Seven-fold. Bajaj, Kapil // Business Today;5/20/2007, Vol. 16 Issue 10, p26 

    The article examines the status of pharmaceutical outsourcing in India. The country's contract research and manufacturing services (CRAMS) market was valued at $895.44 million in 2006. CRAMS had been contributing close to eight percent to the pharmaceutical industry's revenues. It comprised...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics